

 [Print this page](#)
Miscellaneous

* Asterisks denote mandatory information

Name of Announcer *	EU YAN SANG INTERNATIONAL LTD
Company Registration No.	199302179H
Announcement submitted on behalf of	EU YAN SANG INTERNATIONAL LTD
Announcement is submitted with respect to *	EU YAN SANG INTERNATIONAL LTD
Announcement is submitted by *	Ng Pei Shan
Designation *	Company Secretary
Date & Time of Broadcast	19-Jul-2012 17:13:49
Announcement No.	00050

>> Announcement Details

The details of the announcement start here ...

Announcement Title *

Description

Attachments

 [Incorporation_of_Scyrec.pdf](#)
 Total size = **23K**
 (2048K size limit recommended)

EU YAN SANG INTERNATIONAL LTD
(Company Registration Number: 199302179H)

INCORPORATION OF A JOINT VENTURE COMPANY IN SINGAPORE
- SCYREC PTE. LTD.

The Board of Directors of Eu Yan Sang International Ltd (“EYS”) wishes to announce that its wholly-owned subsidiary, EYS Ventures Pte Ltd has formed a joint venture company with CellResearch Corporation Pte Ltd (“CRC”).

The joint venture company, Scyrec Pte. Ltd. (“Scyrec”) is incorporated with a paid-up capital of S\$2 divided into 2 ordinary shares. Scyrec will focus on combining EYS’s expertise in natural and traditional wellness with CRC’s stem cell technologies to drive development of innovative solutions in today’s rapidly evolving healthcare and wellness landscape.

The above investment is funded by internal sources and is not expected to have any material impact on the earnings per share or the net tangible assets per share of EYS for the current financial year.

Other than the interest as disclosed in the holding company in accordance with Section 166 of the Companies Act, none of the Directors and the controlling shareholders of EYS have any interest, direct or indirect, in this transaction.

CRC, a privately held Singapore biotechnology company is a pioneer in the development of Cord Lining Stem Cells (CLSC) technology for stem cell regenerative medicine and therapy as well as a supplier of high quality low passage primary cell culture systems.

BY ORDER OF THE BOARD

Submitted by Ng Pei Shan, Company Secretary, on 19/07/2012 to the SGX.